Coronavirus

Though it failed to meet its primary study endpoints, post hoc analysis of SNG001 showed the inhalable reduced the risk of severe COVID-19 disease and death in high-risk patients.

Stage 2/3 trials are underway to test the efficacy of J08, a potent monoclonal antibody, to prevent and treat current and future COVID-19 variants.

Over half of patients admitted with positive SARS-CoV-2 testing received antibiotics, but evidence of bacterial infection is uncovered in far fewer cases. We may already be seeing the effects of antibiotic overprescribing.

COVID-19 patients who do not speak English faced worse hospital outcomes during the first wave of the pandemic.

A study of pregnant women positive for COVID-19 at delivery found no evidence of vertical transmission, but increased gastrointestinal problems in their newborn infants.

A comparison of COVID-19 PCR tests and rapid self-tests found self-tests to be highly accurate and user-friendly for children.

At 1 year after COVID-19 infection, children’s neutralizing antibodies only differed by vaccination status.

The federal agency authorized the therapy as a standalone treatment via a revised EUA in July of last year.

Despite a significantly slower than expected COVID-19 vaccine rollout, Novavax reports early 2022 as its first profitable quarter.

The higher the gestational age when pregnant women received a COVID-19 vaccine, the higher the serological titers at birth.

Children living with HIV had a similar immune response to mRNA COVID-19 vaccination as children without HIV.

Investigators examined whether rapid antigen tests were less sensitive to variants of concern. Though the tests detected Omicron, all but 1 were less effective in detecting the Delta variant.

Using monoclonal antibodies as post-exposure prophylaxis could be a cost-effective approach to battling COVID-19 in scenarios that include high transmission of susceptible variants, a new study suggests.

JAMA study reveals use of dexamethasone and others in non-hospitalized patients with mild to moderate illness.

Investigators identify 11 crucial “protection-defining genes” that prevent a severe disease response to COVID-19 infection.

The federal agency revised the vaccine’s Emergency Use Authorization after an analysis of the risk for thrombosis with thrombocytopenia syndrome (TTS).

Medicago’s plant-based vaccine, Covifenz, was 69.5% effective against symptomatic COVID-19 infection and 78.8% effective against moderate-to-severe disease.

The number of Americans who opt for an additional booster dose of a COVID-19 vaccine may be limited.

Researchers looked at the serial use of homologous and heterologous boosters in open-label clinical trials across 10 US sites.

Researchers sought to assess antibiotic prescriptions associated with COVID-19 outpatient visits in Medicare beneficiary patients over the course of a year during the pandemic.

Historically low incidence of dengue in southeast Asia and Latin America linked to COVID-19 restrictions suggests potential future interventions.

Dr. Simon Portsmouth of Shionogi discusses the trial results of their once-daily oral COVID-19 antiviral, S-217622, as well as the significance of the therapy as vaccine efficacy wanes in the age of Omicron.

Correlating immune response to COVID-19 vaccination in persons with HIV to their CD4 T-cell count could inform optimal vaccine strategy.

PrEP prescription initiations and fills dropped during the early parts of the COVID-19 pandemic, according to investigators from the NY State Department of Health.

Utilization of ambulatory care services declined during the COVID-19 pandemic, especially among socioeconomically disadvantaged Americans.

Cancer increased risk of COVID-19 among the vaccinated, with subsequent "significant and substantial" hospitalizations and mortality.

Ensovibep, the COVID-19 antiviral treatment developed by Novartis and Molecular Partners, is facing delays in its quest for emergency authorization after the FDA indicated more study data is required.

If authorized, this would be the first vaccine applicable to the youngest pediatric group.

A recent study examined whether immune response to the Pfizer-BioNTech COVID-19 vaccine differed by age and gender.

Lasting 505 days, investigators documented the longest known COVID-19 infection. The research, presented at ECCMID, also found one of the first cases of occult COVID-19, in which a patient who tests negative is later found to have ongoing COVID-19.